BMSN
RGBP
FinancialBuzz.com News Commentary
NEW YORK, November 17, 2017 /PRNewswire/ --
According to a report by Grand View Research (GVR), the global biotechnology market is expected to reach USD 727.1 billion by 2025. Major technological advancements in segments such as regenerative medicine and genetics in diagnostics are important drives for the future of biotechnology. Innovative companies in the industry are engaged in large clinical trials and strong R&D investments for cancer therapeutics, as oncology is one of the most promising areas of focus in the biotech industry. Regen Biopharma, Inc. (OTC: RGBP), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), ImmunoGen, Inc. (NASDAQ: IMGN).
"Rising incidence of oncology diseases is anticipated to drive the demand for next-generation cancer diagnostic tests. These tests are expected to facilitate early diagnosis and enable efficient prognosis of various forms of cancer, which in turn, is expected to positively influence progress of this vertical over the forecast period. Development and introduction of product offerings by a number of large entities is a significant factor expected to provide lucrative growth avenues to this market, active participation of global organizations, such as National Cancer Institute, Cancer Research Institute, National Foundation for Cancer Research, and Cancer Research UK, are supportive of the projected sector progress," GVR reports.
Regen BioPharma, Inc. (OTCQB: RGBP) announced breaking news after the market close that it has, "commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders."
"The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward - if inhibiting the checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid arthritis, lupus, colitis and many other autoimmune diseases," says David Koos, Ph.D., Chairman and CEO of Regen. "Our program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control of toxicity and intellectual property protection."
